Opinion of the Transparency Council – fenoterol hydrobromide + ipratropium bromide
At its meeting on 9 June 2025, the Transparency Council adopted opinion No. 105/2025 on the reimbursement of medicines containing the active substances fenoterol hydrobromide + ipratropium bromide for indications, dosages or methods of administration other than those specified in the Summary of Product Characteristics